KB-1304

JNJ043-hIgG1

Home » Antibody » JNJ043-hIgG1

Background

Talquetamab (JNJ-63483043) is an innovative investigational drug that offers a new approach to the treatment of multiple myeloma. It is a ready-to-use, off-the-shelf immunotherapy that targets both GPRC5D and CD3 through bispecific antibody technology. GPRC5D is a highly expressed target on multiple myeloma cells, while CD3 is the main component of the T cell receptor (TCR) and plays a critical role in activating T cells. By targeting both of these targets simultaneously, Talquetamab can activate T cells more effectively, attack multiple myeloma cells, and reduce side effects.

Specifications

Catalog Number:
KB-1304
Cell Line Name:
JNJ043-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
GPRC5D
Species Reactivity:
Human
Application:
ELISA | FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2¦Ìm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20¡ãC to -80¡ãC; Stored at 2-8¡ãC for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS

References

1. Dimopoulos?MA, Richardson?PG, Moreau?P, Anderson?KC.?Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol?2015;12:42¨C54. 2. Atamaniuk?J, Gleiss?A, Porpaczy?E, Kainz?B, Grunt?TW, Raderer?M, et al?Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest?2012;42:953¨C60.
Please enable JavaScript in your browser to complete this form.